A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection
Journal
Hepatology International
Journal Volume
4
Journal Issue
2
Pages
516-522
Date Issued
2010
Author(s)
Abstract
Purpose: Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection. Methods: We compared baseline hepatitis B viral markers in 317 patients who were enrolled in a prospective study and identified the frequency of these tests in immune-tolerant (IT) patients, in inactive carriers, and in patients with either hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis or cirrhosis. Results: IT patients were youngest (median age 27 years) and HBeAg-negative patients with cirrhosis were oldest (median age 58 years) (p = 0.03 to <0.0001). The male to female ratio was similar both in IT patients and in inactive carriers, but there was a male preponderance both in patients with chronic hepatitis and in patients with cirrhosis (p < 0.0001). The A1896 precore mutants were most prevalent in inactive carriers (36.4%) and HBeAg-negative patients with chronic hepatitis (38.8%; p < 0.0001), and the T1762/A1764 basal core promoter mutants were most often detected in HBeAg-negative patients with cirrhosis (65.1%; p = 0.02). Genotype A was detected only in 5.3% of IT patients, and genotype B was least often detected in both HBeAg-Positive patients with chronic hepatitis and cirrhosis (p = 0.03). The hepatitis B viral DNA levels were lowest in inactive carriers (2.69 log10 IU/mL) and highest in IT patients (6.80 log 10 IU/mL; p = 0.02 to <0.0001). At follow-up, HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for 57 of 64 (89.1%) liver-related deaths (p < 0.0001). Conclusion: Differences in baseline hepatitis B viral markers were detected in patients in various clinical stages of hepatitis B virus infection. HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for the majority of the liver-related fatalities. ? 2010 The Author(s).
Subjects
Basal core promoter mutant; Chronic hepatitis; Cirrhosis; Genotype; HBeAg; HBV DNA; Immune tolerant; Inactive carriers; Precore mutant
SDGs
Other Subjects
alanine aminotransferase; albumin; aspartate aminotransferase; bilirubin; biological marker; hepatitis B(e) antigen; virus DNA; adult; article; comparative study; controlled study; death; female; follow up; genotype; health status; hepatitis B; human; immunological tolerance; liver cirrhosis; major clinical study; male; priority journal; promoter region; prospective study; virology; virus mutant
Type
journal article